News|Articles|March 6, 2026

Measles Update: March 6, 2026

The latest CDC numbers show a 12.76% increase of measles cases from week-to-week. This is a slight decrease in the number of cases from last week where there was a 15.7% increase. The data also shows outbreaks in 3 new states.

Today, the Centers for Disease Control and Prevention (CDC) reported there were 1,281* cases of measles in the US as of March 5, 2026. Week-over week, that is an additional 145 cases and a 12.76% increase. Last week, the federal agency reported there was 1,136* confirmed cases.1 This marks a slight decrease in the number of cases from the previous week that saw a 15.7% increase in cases the week ending (February 27).

This Week's Measles Summary Snapshot

Reviewing the week-to-week measles CDC data, there has been an increase in the number of new measles cases and the percentage of cases. And the number of outbreaks and jurisdictions (states) have increased as well.

CDC said there were 1,277 measles cases in 31 jurisdictions: Alaska, Arizona, California, Colorado, Florida, Georgia, Idaho, Illinois, Kentucky, Maine, Massachusetts, Minnesota, Missouri, Nebraska, New Mexico, New York City, New York State, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, South Dakota, Texas, Utah, Vermont, Virginia, Washington, and Wisconsin. A total of 4 measles cases were reported among international visitors to the US. 1

The latest numbers show 3 more jurisdictions (states) now have outbreaks compared to the previous week.

The federal agency reports “there have been 12 new outbreaks** reported in 2026, and 89% of confirmed cases (1,137 of 1,281) are outbreak-associated (237 from outbreaks in 2026 and 900 from outbreaks that started in 2025).” 1

Predicting Measles Incidence Rates, Healthcare Costs

The Yale School of Public Health did a modeling analysis that showed a sustained 1% annual decline in MMR vaccine coverage could lead to more than 17,000 measles cases, 4,000 hospitalizations, and 36 preventable deaths each year.2 The analysis predicts that over the next 5 years, declining measles vaccination rates could cost $1.5 billion annually and add approximately $7.8 billion in cumulative costs.2

*It is important to note that the CDC says on its website that the federal agency is aware of probable measles cases being reported by jurisdictions. However, the data on this page only include confirmed cases that jurisdictions notified the CDC about. Therefore, there could be higher numbers in the US overall.

**CDC reports the cumulative number of measles outbreaks (defined as 3 or more related cases) that have occurred this year in the US; states have the most up-to-date information about cases and outbreaks in their jurisdictions.

References
1.Measles Cases and Outbreaks. CDC. March 6, 2026. Accessed March 6, 2026.
https://www.cdc.gov/measles/data-research/index.html
2.More Illness, Greater Cost Spotlight Brief: Childhood Immunizations. Common Health Coalition. Accessed March 6, 2026.
chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://commonhealthcoalition.org/wp-content/uploads/2026/02/SpotlightBrief_ChildImms.pdf




Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.